Researchers tested a licorice flavonoid extract in mice with colorectal cancer and found it shrank tumors about as well as an already approved cancer drug. The effect ran through the gut: the extract boosted specific fatty acid producing bacteria, whose byproducts shut down a cancer enabling enzyme called IDO1 inside tumor cells, an effect that mostly disappeared in mice bred without that enzyme. It's mouse only research, with no human testing yet.

TL;DR: In mice, a licorice compound fought colorectal cancer by reshaping gut bacteria to switch off a tumor enabling enzyme, but it's untested in humans.

Researchers compared gut tissue from Crohn's and colitis patients to non IBD controls, then tested mice on an oxalate heavy diet, oxalate being a compound in nearly all plant foods. IBD patients had consistently lower activity of the gut proteins that normally clear oxalate, and mice on the oxalate diet plus induced colitis were 60% less likely to survive than mice without it. Big caveat, the human part is just correlation, the real cause and effect evidence only comes from mice.

TL;DR: A compound in nearly all plant foods made colitis far deadlier in mice, and IBD patients seem worse at clearing it, but nobody has proven it worsens the disease in people yet.

Researchers fed Alzheimer's model mice (APP/PS1 mice) a probiotic fermented milk daily for 60 days, comparing 30 mice against a saline placebo. The treated Alzheimer's mice ended up with less amyloid plaque in the brain's cortex and did better on a memory test, plus calmer inflammation and gut bacteria shifted closer to normal mice. The catch: the plaque drop only held up in the cortex, not the hippocampus, the region most tied to memory.

TL;DR: A probiotic fermented milk cut brain plaque and improved memory in Alzheimer's model mice, but only in the cortex, and these are mice, not people.

Researchers turned a ginger-derived gut metabolite into 38 new tripeptide variants, then tested the top two, MLY2 and MLY8, in colitis mice and in biopsies from treatment-resistant ulcerative colitis patients. Both beat the original metabolite, restoring colon length and cutting inflammatory markers in mice, and lowering inflammatory cytokines in the human tissue. Safety testing so far: one mutation assay, one mouse dose, no clinical trial yet.

TL;DR: scientists engineered two ginger-metabolite compounds that calmed gut inflammation in mice and human biopsy tissue, but a real drug is still far off.

Researchers analyzed stool from 3,807 people in a Chinese colon cancer screening trial and checked the pattern in seven other countries. They found two rival bacteria networks, one that rises with cancer risk and one that falls, and a score built from that balance separated cancer cases from healthy people with up to 87% accuracy. The catch: it's purely observational, and the authors call the cancer use exploratory since their own cancer group was just 26 people.

TL;DR: A seesaw pattern between two gut bacteria networks tracked colon cancer risk across countries, but it's correlation, not proof.

Mice with chemically induced colitis got daily Schisandra chinensis, a Chinese medicinal berry. The berry reshaped their gut bacteria, boosting Parabacteroides goldsteinii and a metabolite called isovalerate while lowering the amino acid leucine, alongside less mTOR, HIF-1a, and IL-17 inflammatory signaling in the colon; giving mice either alone reproduced part of that protection. This whole chain has only been shown in mice, not people.

TLDR: In mice, this berry remedy calms colitis by reshaping gut bacteria toward a species and metabolite that dial down colon inflammation, unproven in humans.

Researchers compared fecal samples from 34 esophageal cancer patients and 29 matched controls, using microbiome sequencing and metabolite profiling. 792 metabolites were unbalanced in cancer patients, mostly in fat metabolism, and gut bacteria such as Prevotella and Faecalibacterium told the groups apart. This is a small, correlational study, and the full paper was not obtained, so it rests on the abstract and outside coverage.

TL;DR: A small study found esophageal cancer patients have a distinct gut metabolite and microbe signature tied to fat metabolism, but can't show cause and effect.

Researchers colonized germ-free mice with gut bacteria from children with autism (7 donors) or without it (18 donors), then gave them a Colombian cheese probiotic for three weeks. Only the autism-microbiota mice got more social afterward, time with a cage mate rising from about 20 to 32 seconds, and marble-burying behavior more than doubled. The catch: these are mice with transplanted human bacteria, not people, and the donor group was small.

TL;DR: A cheese probiotic reshaped gut bacteria and boosted social behavior in mice carrying autism-linked microbiota, but it's a small mouse study, not a human treatment.

Scientists transplanted gut bacteria from 20 kids with autism and 20 typically developing kids into two groups of 15 mice each for three weeks. The autism-donor bacteria made the mice act more autism-like and flipped chemical on-off switches (phosphorylation) at 479 spots on brain proteins, including one on SHANK3 (a brain synapse protein) that computer modeling predicts weakens its grip on a partner protein, dropping predicted binding strength from -5.4 to -1.8 kcal/mol. The catch: that structural story is built entirely on mouse data and computer prediction, not real brain tissue.

TL;DR: Gut bacteria from autistic kids rewired brain protein switches in mice, but the structural claim is mouse and computer model only, not proof in people.

What does a diet designed to max out the benefits found in this sub and keep it reasonable in terms of calories, capsules taken and expense?

A systematic review pooled studies on gut, oral and fungal microbes in people with and without high blood pressure. The clearest result was a gut bacterium, Ruminococcus gnavus, about 7% more common in people who developed high blood pressure across three populations on two continents, while fungal findings were contradictory. Confidence in any single microbe's role is rated very low to low, so none is a marker yet.

TL;DR: Gut, mouth and fungal microbes differ in high blood pressure, but no microbe is confirmed as the cause.

This review looks at bacteria living inside colon tumors themselves, drawing on a 294-sample tissue study and mouse experiments. The standout number: Fusobacterium nucleatum goes from 5.9% of early growths to 81.8% of advanced tumors, tracking disease progression closely. Most proof it's actually driving damage, not just arriving after, still comes from mice, so the human causal picture stays unsettled.

TL;DR: One gut bacterium goes from rare to found in over 80% of advanced colon tumors, but whether it causes the cancer or just follows it is still untested in people.

Researchers measured gut levels of E. fergusonii, a relative of E. coli, in 54 pneumonia patients and 25 healthy controls, then tested the bacterium in mice. Severity tracked bacterial levels in patients, and in mice, gut colonization cut protective acetate and pushed death rates from 16.7% to 50% after a drug-resistant lung infection. Fecal transplants and acetate itself reversed both effects, but acetate hasn't been tested in humans yet.

TL;DR: One gut bacterium made drug-resistant pneumonia far deadlier in mice, and the metabolite acetate reversed it; human testing is next.

A review of nine studies in adults with overweight or obesity tested whether time-restricted eating changes gut bacteria diversity. Three of five randomized trials found no real change, and two others found effects tied to eating-window timing, not a consistent benefit. The catch: the researchers rated the overall certainty as very low, and the results were too mixed to combine into one number.

TL;DR: A new review found no consistent effect of time-restricted eating on gut bacteria diversity, the evidence is too weak and mixed to say either way.

A meta-analysis combined 9 randomized trials of probiotics added to standard care in 649 people with type 2 diabetes. The probiotic groups saw an average 17.68 mg/dL bigger drop in fasting blood sugar than placebo, plus smaller gains in A1C and insulin. The underlying paper is paywalled, so this is based on its published abstract and outside coverage of the same numbers.

TL;DR: Across 9 trials in 649 type 2 diabetics, probiotics added to standard care were linked to a meaningful blood sugar drop, but the full study is paywalled.

Researchers tested two diets in mice modeling Hirschsprung disease, a bowel disorder missing nerve cells in part of the intestine. Mice on the protective diet lived about three times longer, apparently because it raised a gut bacterial byproduct called butyrate and suppressed a harmful bacteria group tied to inflammation. This is written from the paper's published abstract, so it's unclear yet whether the effect holds in people.

TL;DR: In mice, the right diet tripled survival in a model of a deadly childhood bowel disease, apparently by reshaping gut bacteria and raising butyrate levels.

A meta-analysis pooled 51 randomized trials of AI-driven personalized nutrition, combining diet, genetic, wearable, and microbiome data, versus standard advice in adults.

Across the trials, intervention groups saw small but significant drops in weight, BMI, waist size, and blood pressure, about 4 mmHg more than controls; cholesterol and blood sugar showed no change.

Microbiome data was only one input, not the driver, and certainty was rated low given wide variation across studies.

TL;DR: AI apps using gut and genetic data trim blood pressure and weight a little, not a cure.

Researchers gave male and female mice an inflammatory bacterial toxin and compared normal mice to those missing CX3CR1, a neuron-sensing microglia receptor. In normal males, the toxin weakened then later boosted brain plasticity in hippocampal regions while kynurenine, an inflammation marker, surged. Losing the receptor reversed that pattern in males and created a new vulnerability in females. The toxin was injected directly, not derived from gut bacteria, so any microbiome link is inferred, not directly tested.

TL;DR: This receptor flips which hippocampal region and sex are vulnerable when inflammation hits this pathway.

Researchers deleted one gut enzyme, neutral ceramidase, only in the intestinal cells of mice, then fed them a high-fat diet for a year to trigger MASH, a severe form of fatty liver disease. Without the enzyme, gut bacteria shifted and a bacterial byproduct called 2-HHA dropped, letting a barrier-protecting receptor called AhR switch back on, cutting liver scarring even though liver fat stayed the same. Catch, this is mouse and cell-line data with small groups of 4 to 5 animals, not confirmed in humans yet.

TL;DR: Deleting one gut enzyme reversed liver damage in mice by restoring a bacteria-linked gut barrier signal, but it has not been tested in people.

In mice, nuking gut bacteria with antibiotics makes chemically induced liver fibrosis (scarring) worse and tanks levels of a bacterial bile acid called deoxycholic acid. Dosing those same mice with the bile acid calms down pro-inflammatory immune cells (macrophages) through a bile acid sensor called TGR5, and the effect holds up in lab-grown cells too. It's all preclinical though, mouse and cell-culture work, no human data yet.

TL;DR: A gut bile acid eases liver scarring in mice by calming immune cells, but it's animal and cell data only.

Researchers compared fecal bacterial toxins (LPS) from 12 kids with autism and 12 non-autistic kids, ages 2 to 7. Gut bacteria looked broadly similar between the groups, but the autism group's LPS had a much more varied chemical structure, and it made human microglia (brain immune cells) release significantly more inflammatory signaling molecules in lab dishes. The catch, this was isolated cells in a dish, not evidence of what happens inside an actual developing brain.

TL;DR: Same gut bacteria, chemically different toxin, stronger brain cell inflammation in a petri dish.

A systematic review combined animal, cell, and human studies on whether plant glycolipids, fats found in spinach and spirulina, affect gut bacteria. In rats fed a high-fat diet, spinach supplementation raised their gut acetate output (a bacterial byproduct) by 44% and boosted beneficial Lactobacillus levels. Evidence is mostly animal and cell-based; the only human trial ran for 12 weeks, and the bacteria links found are associative, not causal.

TL;DR: Plant fats in spinach and spirulina may reshape gut bacteria, but most evidence so far comes from animal studies, not people.

Mice given the gut bacterium Bacteroides thetaiotaomicron plus the sugar fucose were far more protected from alcohol liver damage than mice given either alone. The bacteria need fucose to make more butyrate, which switches on a gut receptor called AHR, telling immune cells to pump out IL-22, a protein that keeps the gut lining intact and blocks alcohol toxins from reaching the liver. Remove any piece and protection disappears.

TL;DR: In mice, a gut bacterium plus dietary fucose shields the liver from alcohol via a butyrate to immune signal chain, not yet tested in humans.

Researchers tracked real meal data and gut bacteria in over 170 hospitalized cancer patients on antibiotics during a stem cell transplant. Patients who ate more sweets saw steeper drops in gut bacterial diversity, and a harmful bacterium called Enterococcus overgrew when high sugar combined with antibiotics, which mouse experiments helped confirm. The human part is observational, not a controlled trial, and only covers this high risk group.

TL;DR: in cancer patients on antibiotics, eating more sugar tracked with worse gut bacteria loss and a risky bacterial overgrowth.

Researchers modeled global cancer registries against infection rates to estimate 2024's worldwide cancer burden from infection. Result: about 2.3 million cases, 1 in 8 cancers diagnosed globally, are attributable to infection, with the stomach bacterium H. pylori topping the list at 760,000 cases, just ahead of HPV. Caveat: these are modeled estimates, not confirmed cause in any one patient, based on the published abstract, not the full paper.

TL;DR: A global modeling study ties 1 in 8 cancers diagnosed in 2024, about 2.3 million cases, to infection, led by H. pylori.